外照射放疗后放射性复发前列腺癌的局部挽救治疗:系统评价与荟萃分析
该系统评价纳入28项研究(6项前瞻性、22项回顾性)共1544例患者,评估外照射放疗后局部复发前列腺癌的局部挽救治疗结局。2年无复发生存率在近距离放疗组为84.0%、外照射放疗组为69.0%、冷冻治疗组为58.0%、高强度聚焦超声组为45%。作者认为近距离放疗或外照射放疗再照射在疗效与安全性间平衡最佳,但证据水平低,无法作出强烈推荐。
要点
- 2年无复发生存率:近距离放疗84.0%,外照射放疗69.0%,冷冻治疗58.0%,高强度聚焦超声45%。
- 挽救性前列腺切除术后无复发生存率75%至78.5%,中位随访18至35个月。
- 严重胃肠道毒性:冷冻治疗2%、近距离放疗3%、高强度聚焦超声3%、外照射放疗4%、挽救性前列腺切除术11%。
核心结论
- 对于外照射放疗后局部复发前列腺癌患者,近距离放疗或外照射放疗再照射在疗效与安全性间平衡最佳。
- 由于证据水平低,无法就任何技术的选择作出强烈推荐。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Scopus和Web of Science Core Collection数据库,检索时间为2023年10月,纳入过去20年发表的评估外照射放疗后局部复发前列腺癌局部挽救治疗结局的研究。
- 共纳入28项研究(6项前瞻性、22项回顾性),包括1544例患者。
- 当两项或以上研究报告同一结局时,使用ProMeta 3软件进行荟萃分析,效应量以率及其95%CI估计。
主要发现
- 2年无复发生存率:近距离放疗组84.0%(95%CI 67.0-93.0%),外照射放疗组69.0%(95%CI 42.0-87.0%),冷冻治疗组58.0%(95%CI 43.0-71.0%),高强度聚焦超声组45%(95%CI 38.0-52.0%)。
- 挽救性前列腺切除术后无复发生存率范围为75%至78.5%,中位随访范围为18至35个月。
- 严重胃肠道毒性发生率:冷冻治疗2%,近距离放疗3%,高强度聚焦超声3%,外照射放疗4%,挽救性前列腺切除术11%。
关键数值与推荐
- 2年无复发生存率:近距离放疗84.0%(95%CI 67.0-93.0%),外照射放疗69.0%(95%CI 42.0-87.0%),冷冻治疗58.0%(95%CI 43.0-71.0%),高强度聚焦超声45%(95%CI 38.0-52.0%)。
- 挽救性前列腺切除术后无复发生存率75%至78.5%,中位随访18至35个月。
- 严重胃肠道毒性:冷冻治疗2%,近距离放疗3%,高强度聚焦超声3%,外照射放疗4%,挽救性前列腺切除术11%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To date, radio-recurrent prostate cancer (PCa) ranks as the fourth most common urological malignancy when considering the number of men with localized PCa who undergo radiation treatment and subsequently experience a biochemical recurrence. This systematic review aimed to summarize available evidence about the outcomes of local salvage strategies in patients with local PCa recurrence following primary external-beam radiation therapy (EBRT). METHODS: We conducted a comprehensive bibliographic search on MEDLINE, Scopus, and Web of Science Core Collection databases in October 2023 to identify studies published in the last 20 years evaluating outcomes of local salvage procedures in patients with locally radio-recurrent PCa following EBRT. The meta-analysis was performed using ProMeta 3 software when two or more studies reported the same outcome. The effect size (ES) was estimated using rates reported with its 95% confidence interval (CI). RESULTS: Overall, 28 studies (6 prospective and 22 retrospective) including 1544 patients were included in the review. Two-year recurrence-free survival (RFS) was 84.0% (95% CI: 67.0-93.0%), 69.0% (95% CI: 42.0-87.0%), 58.0% (95% CI: 43.0-71.0%), and 45% (95% CI: 38.0-52.0%), for patients undergoing brachytherapy (BT), EBRT, Cryotherapy and High-Intensity Focused Ultrasound (HIFU), respectively. After salvage prostatectomy, RFS ranged from 75% to 78.5% at a median follow-up ranging from 18 to 35 months. Estimates for severe gastrointestinal toxicity were 2%, 3%, 3%, 4%, and 11% following cryotherapy, BT, HIFU, EBRT, and salvage radical prostatectomy, respectively. CONCLUSIONS: In patients who underwent EBRT as primary treatment, prostate salvage re-irradiation through BT or EBRT represents the modality providing the best balance between efficacy and safety. Unfortunately, due to the low level of evidence, strong recommendations regarding the choice of any of these techniques cannot be made.
引用
- Creta M, Shariat SF, Marra G, et al. Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 39223232. doi:10.1038/s41391-024-00883-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。